Cofounder and CEO at HealthTraining Lab SL and Intelligent System Vitale SL. Both companies developing digital systems for the improvement and treatment of pathologies and improving lifestyles through personalized nutrition, physical activity and stress and sleep management. Jorge leads a team of 25 people that already gives service to more than 4 million users across Europe and Latin America.

Dr. Rodolfo J. Galindo graduated with Summa Cum Laude from the Institute of Medical Sciences of the University of Havana, Cuba. He completed his Internal Medicine and Endocrinology fellowship at the Albert Einstein College of Medicine and North Shore University Hospital, in New York. After graduating from his fellowship, he joined the faculty of the Mount Sinai School of Medicine and served as the Director of the Hospital Diabetes. Dr. Galindo joined the faculty of Emory University in 2017, as a clinical researcher on diabetes. Dr. Galindo’s areas of clinical and research interest include management of diabetes in patients with advanced renal failure, with post-transplant diabetes, and in diabetes in hospitalized patients. He is very interested in using diabetes technology in these populations and has several ongoing research projects on the use of CGM technology on these populations. His clinical research program is currently funded by the NIH- NIDDK, NIDDK-sponsored Georgia Center for Diabetes Translational Research, foundations and investigator-initiated studies.

Dr. Jose Garcia-Tirado received his Ph.D. in Control Systems Engineering (2014) from the Universidad Nacional de Colombia. At the end of 2017, Dr. Garcia- Tirado joined the Center for Diabetes Technology (CDT) as Research Associate. In March 2021, Dr. Garcia-Tirado was appointed as Assistant Professor of the CDT. His research interests include systems identification, estimation theory, receding-horizon control and estimation, and modeling of glucose homeostasis. In his current work, Dr. Garcia-Tirado is mainly devoted to the refinement of a fully automated insulin delivery system (a.k.a. the artificial pancreas) to tackle automatically meaningful glycemic disturbances caused by meal intake and physical activity. Additional interests encompass but are not limited to the orchestrated use of SGLT2i and Automated Insulin Delivery and individualization of physiological models and behavioral patterns (eating and exercise patterns) from CGM, insulin pump, meal records, and activity tracker data.

Satish K. Garg is Professor of Medicine and Pediatrics at the Adult Clinic of the Barbara Davis Center for Diabetes of the University of Colorado School of Medicine in Denver, Colorado. He joined the faculty of the Barbara Davis Center in 1992 and became the founder and director of the Adult Clinic. He established and holds two Garg Endowed Chairs (clinical and clinical research) at the University of Colorado Denver. His team is one of the top teams world-wide in clinical trials involving insulin analogues and novel methods of insulin delivery (pens, pumps, oral, buccal and inhaled) and non-insulin adjunctive treatment options for Type 1 Diabetes. Other areas of interest include continuous glucose monitors, evaluating the accuracy of meters at high altitude, and artificial pancreas systems. Dr. Garg received a medical degree in medicine at Punjab University in Ludhiana, India, where he also completed a residency in internal medicine at Christian Medical College and Hospital. He completed fellowships in adult endocrinology and diabetes at the Post Graduate Institute of Medical Education and Research (PGIMER) in Chandigarh, India, and in pediatric endocrinology and diabetes at the University of Colorado at Denver and Health Sciences Center. He is board certified in internal medicine and endocrinology and diabetes. Dr. Garg is the Editor in chief of Diabetes Technology and Therapeutics journal since 2006 and Chair of the planning committee for Clinical Therapeutics and New Technology area for 2007 and 2008 Annual American Diabetes Associations meetings. He is the director of ATDC Diabetes Conference, in Keystone, since 2005. He is a member of the many Endocrine and Diabetes Societies such as: International Diabetes Federation, the American Diabetes Association, the Endocrine Society of India, and the European Association of Study for Diabetes, the Regional Pediatric Endocrine Society of Colorado, the Research Society for Study of Diabetes Mellitus, and numerous other professional societies in both the United States and India. He is an international lecturer and speaker—he received several international oration awards—and has published many chapters in the books, on the editorial boards for many of the diabetes journals globally and has published more than 325 original manuscripts in peer-review journals.

Matthew Garza joined the diaTribe Foundation in 2020 and is currently a senior associate in charge of diaTribe’s stigma program area, helping build a multi-stakeholder initiative to address diabetes stigma in the US, which included the launch of dStigmatize.org. Garza is also the managing editor of diaTribe’s education resources and weekly newsletter, diaTribe Learn. Prior to joining diaTribe, Garza received a B.S. in Biomedical Engineering from Johns Hopkins University’s Whiting School of Engineering and a minor in the Study of Women, Gender, and Sexuality. He is also an alumnus of the Harvard Medical School’s Effective Writing for Healthcare certificate program. Garza has a passion for understanding how stigma impacts health outcomes for marginalized groups including those with chronic conditions and the LGBTQ+ community.

She is the Research Director of the Cardiometabolic Risk UNIT and of Mass Spectrometry Laboratory at CNR-IFC in Pisa Italy; also appointed as adjunct Professor at the Diabetes Division of the University of Texas Health Science Centre (UT Health) in San Antonio, Texas, USA and associate researcher in Sant'Anna School of Advanced Studies in Pisa. She has more than 25 year experience in leading national and international scientific projects investigating metabolic diseases including obesity, non alcoholic fatty liver disease (NAFLD) and type 2 diabetes. These include alterations in glucose and lipid metabolism, insulin resistance and ectopic fat accumulation collaborating with many institutions in Europe and United States. She is currently the chair of the EASD NAFLD Study Group, which provides a joint forum for diabetologists and hepatologists to explore the diagnosis, pathogenesis and treatment of NAFLD and NASH, and the chair of the EASD EGIR Study Group which focuses on insulin action and secretion. She was part of the EASL-EASD-EASO committee for the writing of the “Clinical Practice Guidelines for the management of NAFLD” (2016). She more than 300 publications as articles in international journals and book chapters with a global H index of 87 and more than 30,000 citations.

Dr. Gölz is a diabetologist. Since 2004, he has been running a practice in Esslingen, southwest of Germany. His medical career began in Stuttgart in a cross-regional Diabetes Centre with a focus education. The main interest of Dr. Gölz is diabetes technology, particularly continuous glucose monitoring and insulin pump therapy. He is well informed in this field, co-authoring the type 1 diabetes therapy guidelines published by the German Diabetes Association (DDG). Dr. Gölz is also a member of the “Digitalization” Commission of the DDG.